Company intelligence / Profile preview

Neuco United

Hong Kong, China

Ownership: Private
Development stage: Other

Overview

AR1001 is in a global, multicenter, Phase 3 clinical trial in early-stage Alzheimer’s disease; preclinical and clinical data suggest safety, blood-brain barrier permeability, and potential efficacy in slowing cognitive decline in early AD, with a focus on neuroprotection and anti-inflammatory action

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

AriBio (for co-development and global trial of AR1001)Fosun Pharma (exclusive licensing and planned technology transfer for AR1001 in Greater China)

Beyond the preview

Go deeper on Neuco United.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neuco United.

Explore the full profile